Recursion Pharmaceuticals (RXRX) Payables: 2020-2025
Historic Payables for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $13.9 million.
- Recursion Pharmaceuticals' Payables rose 516.59% to $13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.9 million, marking a year-over-year increase of 426.46%. This contributed to the annual value of $21.6 million for FY2024, which is 441.14% up from last year.
- Per Recursion Pharmaceuticals' latest filing, its Payables stood at $13.9 million for Q3 2025, which was down 27.85% from $19.3 million recorded in Q2 2025.
- In the past 5 years, Recursion Pharmaceuticals' Payables registered a high of $25.1 million during Q1 2025, and its lowest value of $2.3 million during Q3 2024.
- Its 3-year average for Payables is $9.8 million, with a median of $5.0 million in 2023.
- Per our database at Business Quant, Recursion Pharmaceuticals' Payables tumbled by 54.44% in 2024 and then soared by 516.59% in 2025.
- Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Payables stood at $2.9 million in 2021, then surged by 60.98% to $4.7 million in 2022, then dropped by 14.71% to $4.0 million in 2023, then surged by 441.14% to $21.6 million in 2024, then surged by 516.59% to $13.9 million in 2025.
- Its Payables was $13.9 million in Q3 2025, compared to $19.3 million in Q2 2025 and $25.1 million in Q1 2025.